Rovi, ES0157261019

Barron's sees EUR 76.76 target for Rovi stock

Published on 10/13/2026 at 14:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rovi reports nine-month results on November 5, 2026. Rovi stock costs EUR 57.73 on October 13, 2026, down 1.32 percent versus October 12 Xetra close.

Array
Rovi, ES0157261019, Illustration mit AI erstellt.
Rovi, ES0157261019, Illustration mit AI erstellt.

On October 8, 2026, Barron's listed an average Rovi target of EUR 76.76 from 10 ratings. That target lies 32.97 percent above the EUR 57.73 price at Lang & Schwarz on October 13, 2026 at 2:29 p.m. CEST.

First-half growth sets the baseline

Rovi's investor page reported total revenue growth of 13.20 percent in the first half of 2026 and gross margin expansion of 6.50 percentage points, giving the upcoming report a clear operating benchmark. The figures cover the period ended June 30, 2026 and refer to the company's reported results.

The same investor calendar schedules first nine months 2026 financial results for November 5, 2026, according to Rovi. That date is within 45 days and gives investors the next defined checkpoint for revenue, margins and contract manufacturing activity.

Stock sits 33.41 percent below its high

At EUR 57.73, Rovi stock was 33.41 percent below its 52-week high of EUR 86.70 and 8.72 percent above its 52-week low of EUR 53.10 on October 13, 2026. The current price therefore sits materially closer to the annual low than to the annual high.

Market capitalization was EUR 3.0 billion on October 13, 2026, while the price-to-earnings ratio was 15.93 and the dividend yield was 1.34 percent on October 8, 2026. The valuation figures provide a second lens alongside the analyst average target, but they do not establish a forecast.

Comparison with peers

Rovi (Madrid, EUR): minus 1.32 percent, price-to-earnings ratio 15.93, market capitalization EUR 3.0 billion

Grifols (Madrid, EUR): minus 1.94 percent, price-to-earnings ratio 14.67, market capitalization EUR 6.7 billion

Pharma Mar (Madrid, EUR): minus 0.51 percent, price-to-earnings ratio 20.81, market capitalization EUR 1.2 billion

Next report gives investors a date

The November 5 report is the next scheduled event in Rovi's investor calendar. Until then, the main measurable reference points are the 13.20 percent first-half revenue increase, the 6.50 percentage-point gross-margin expansion and the EUR 76.76 analyst average target.

Rovi stock trades below the Xetra close

Rovi stock was trading at EUR 57.73 at Lang & Schwarz on October 13, 2026 at 2:29 p.m. CEST, down 1.32 percent versus the Xetra close of October 12, 2026 at EUR 58.50. The bid was EUR 57.45 and the ask was EUR 58.00.

The further course of trading is shown by the continuously updated real-time quote of Rovi stock.

Rovi market data

  • Company: Laboratorios Farmaceuticos Rovi, S.A.
  • ISIN: ES0157261019
  • Ticker: ROVI
  • Primary exchange: Madrid Stock Exchange
  • Price Lang & Schwarz (as of October 13, 2026, 2:29 p.m. CEST): EUR 57.73
  • Change versus Xetra close: minus 1.32 percent
  • Xetra close (October 12, 2026): EUR 58.50
  • Market capitalization: EUR 3.0 billion (as of October 13, 2026)
  • 52-week range: EUR 53.10-86.70 (as of October 13, 2026)
  • Sector / Industry: Healthcare / Drug Manufacturers - Specialty & Generic

Market context: Market report IBEX 35.

More news and analyses on Rovi stock

Disclaimer...

en | ES0157261019 | ROVI | boerse | 70314966 | bgmi